Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients

Dalbavancin, approved for the treatment of pediatric and adult patients with acute bacterial skin and skin structure infections, has a terminal half-life of >14 days allowing administration as a single-dose regimen. METHODS: We developed a population pharmacokinetic (PK) model using 1124 dalbavan...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrothers, Timothy J., Lagraauw, H. Maxime, Lindbom, Lars, Riccobene, Todd A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Antimicrobial Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835671/
https://www.ncbi.nlm.nih.gov/pubmed/36638392
http://dx.doi.org/10.1097/INF.0000000000003764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835671/
https://www.ncbi.nlm.nih.gov/pubmed/36638392
http://dx.doi.org/10.1097/INF.0000000000003764

Ejemplares similares